| Maintaining higher dose at follow-up visit |
| Dose escalation at follow-up visit |
| ||
| Fesoterodine 156 | Solifenacin 48 | p value | Fesoterodine 194 | Solifenacin 134 | p value |
Women, n (%) | 235 (86.5) | 40 (83.3) | NS | 144 (74.2) | 98 (73.1) | NS |
Age, mean (SD), years | 62.2 (12.3) | 59.4 (13.7) | NS | 61.4 (10.8) | 60.8 (12.5) | NS |
BMI, mean (SD), Kg/m2 | 26.0 (4.3) | 25.5 (4.4) | NS | 26.5 (3.6) | 26.1 (3.7) | NS |
OAB evolution time, mean (SD), months | 14.5 (22.2) | 17.9 (21.8) | NS | 21.6 (69.0) | 17.4 (21.6) | NS |
Concomitant disease, mean (SD) | 2.9 (2.6) | 2.9 (2.5) | NS | 3.3 (2.7) | 3.4 (2.8) | NS |
Concomitant disease, n (%) | 128 (82.1) | 37 (77.1) | NS | 170 (87.6) | 113 (84.3) | NS |
Hypertension | 63 (49.2) | 11 (29.7) | 0.040 | 85 (50.0) | 64 (56.6) | NS |
Cardiovascular disease | 20 (15.6) | 6 (11.1) | 0.008 | 13 (7.6) | 18 (15.9) | 0.033 |
Urinary tract infections | 62 (48.4) | 16 (43.2) | NS | 77 (45.3) | 32 (28.3) | 0.004 |
Mellitus diabetes | 25 (19.5) | 7 (18.9) | NS | 32(18.8) | 21 (18.5) | NS |
Depression | 35 (27.3) | 9 (24.3) | NS | 38 (22.3) | 28 (24.7) | NS |
Insomnia | 42 (32.8) | 12 (32.4) | NS | 50 (29.4) | 49 (43.4) | 0.016 |
Obesity (BMI ≥ 30 Kg/m2) | 29 (22.7) | 6 (16.2) | NS | 42 (24.7) | 26 (23.0) | NS |
Rheumatic disease | 18 (14.1) | 9 (24.3) | NS | 36 (21.2) | 28 (24.8) | NS |
Fibromyalgia | 2 (1.6) | 3 (8.1) | NS | 15 (8.8) | 21 (18.6) | 0.018 |
*BPH | 16/21 (76.2) | 3/8 (37.5) | NS | 33/50 (66.0) | 21/36 (58.3) | NS |